Dose-Escalation Study of SCD-101 in Sickle Cell Disease

NCT02380079 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Sickle-Beta Zero Thalassemia

Interventions

DRUG: SCD-101

Sponsor

Invenux, LLC

Collaborators

[object Object]